References
- Ohashi K., Gillies H. C., Rogers H. J., Harper P. G. Pharmacoki-netics of Idarubicin (IMI-30): An orally administered anthra-cycline. Proc 14th Int Congr on Chemother 1986; 328: 18–56
- Robert J., Rigal-Huguet F., Hurteloup P. Pharmacokinetics of Idarubicin administered per os in leukemia patients. Proc ECCO-4 1987; 299
- Bastholt L., Dalmark M. Phase II study of Idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients. Cancer Treat Rep 1987; 71: 451–4
- Lionetto R., Pronzato P., Conte P. F., Sertoli M. R., Amoroso D., Rosso R. Idarubicin in advanced breast cancer: a phase II study. Cancer Treat Rep 1986; 70: 1439–40
- Martoni A., Pacciarini M. A., Panutti F. Activity of 4-demeth-oxydaunorubicin by the oral route in advanced breast cancer. Eur J Cancer Clin Oncol 1985; 21: 803–6
- Lopez M., DiLauro L., Papaldo P., Lazzaro B., Ganzina F., DiPietro N. Phase II trial with oral Idarubicin in advanced breast cancer. Invest New Drugs 1986; 4: 39–42
- Hoogstraten B., Fabian C. A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials 1979; 2: 101–9
- Creech R. H., Catalano R. B., Hopson R. C. A comparison of standard dose Adriamycin and low dose Adriamycin as primary chemotherapy for metastatic breast cancer. Proc AACR. 1980; 21–142
- Gundersen S., Kvinnsland S., Klepp O., Kvaløy S., Lunds E., Høst H. Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 1986; 22: 1431–4
- Sigurdsson H., Johansson-Teje I., Aspegren K., et al. Weekly-dose doxorubicin (WDA) in advanced breast cancer. Ra-diother Oncol 1986; 7: 133–9
- Torti F. M., Brestow M. R., Howes A. E., et al. Reduced cardio-toxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Int Med 1983; 99: 745–9
- Weiss A. J., Metter G. E., Fletcher W. S., Wilson W. L., Grage T. B., Ramirez G. Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976; 60: 813–22
- Chlebowski R. T., Paroly W. S., Pugh R. P., et al. Adriamycin given as a weekly schedule without a loading dose: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980; 64: 47–51
- Smith D. B., Howell D. B. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer. Eur J Cancer Clin Oncol 1987; 23: 391–4
- Krarup-Hansen A., Andersen E., Elbak K., Rasmussen S. N., Dalmark M. Phase I study of weekly 4-demethoxydaunorubi-cin (DMDR) by oral route in patients with solid tumors. Proc ECCO-4, (Abstract 274). 1987
- World Health Organization. Handbook for reporting results of cancer treatment. WHO, Geneva 1979
- Elbaek K., Ebbehoj E., Jakobsen A., et al. Pharmacokinetics of long-term oral Idarubicin in patients with advanced breast cancer. Clin Pharmacol Ther., (Accepted for publication.)
- Bonadonna G., Beretta G., Tancini G., et al. Adriamycin (NSC-123127) studies at the Istituto Nazionale Tumori, Milan. Cancer Chemother Rep Part 1975; 6: 231–45